摘要:
The present invention pertains to polypeptides derived from the timothy grass pollen allergen Phl p 7. The polypeptides display reduced allergen activity and are useful as allergy vaccines for the treatment of sensitized allergic patients and for prophylactic vaccination.
摘要:
The present invention pertains to polypeptides derived from the timothy grass pollen allergen Phi p 7. The polypeptides display reduced allergen activity and are useful as allergy vaccines for treatment of sensitized allergic patients and for prophylactic vaccination.
摘要:
The present invention pertains to polypeptides derived from the timothy grass pollen allergen Phl p 7. The polypeptides display reduced allergen activity and are useful as allergy vaccines for treatment of sensitized allergic patients and for prophylactic vaccination.
摘要:
The present invention relates to a pharmaceutical composition containing a peptide and a pharmaceutically acceptable carrier or diluent wherein the peptide has a length of 8 to 50 amino acids, at least three preferably consecutive amino acids of the peptide are identical to at least three amino acids which appear in close vicinity on the molecular surface of an allergenic protein, and said at least three amino acids are solvent-exposed amino acids in the allergenic protein. The invention also concerns a method for the preparation of the pharmaceutical composition.
摘要:
Hypoallergenic mosaic antigens assembled from naturally-occurring allergens are disclosed herein. Also disclosed are methods of making such hypoallergenic mosaic antigens, particularly those derived from plant allergens such as timothy grass pollen (Phl p 1 and Phl p 2) and birch pollen (Bet v 1). In a particularly preferred embodiment, the method of making the hypoallergenic mosaic antigen involves the steps of (a) cleaving a naturally-occurring allergen into at least two, preferably at least three non-overlapping peptide fragments and (b) recombining the peptide fragments such that the mosaic antigen includes all or substantially all of the amino acids of the original naturally-occurring allergen, though in a different order.
摘要翻译:本文公开了由天然存在的变应原组装的低过敏性花叶病毒抗原。 还公开了制备这种低变应原性花叶病毒抗原的方法,特别是衍生自植物过敏原如Timothy草花粉(Phl p 1和Phl p 2)和桦树花粉(Bet v 1)的那些。 在特别优选的实施方案中,制备低变应原性镶嵌抗原的方法包括以下步骤:(a)将天然存在的变应原切割成至少两个,优选至少三个非重叠的肽片段,和(b)将肽片段 马赛克抗原包括原始天然存在的变应原的所有或基本上全部的氨基酸,尽管以不同的顺序。
摘要:
Hypoallergenic mosaic antigens assembled from naturally-occurring allergens are disclosed herein. Also disclosed are methods of making such hypoallergenic mosaic antigens, particularly those derived from plant allergens such as timothy grass pollen (Phl p 1 and Phl p 2) and birch pollen (Bet v 1). In a particularly preferred embodiment, the method of making the hypoallergenic mosaic antigen involves the steps of (a) cleaving a naturally-occurring allergen into at least two, preferably at least three non-overlapping peptide fragments and (b) recombining the peptide fragments such that the mosaic antigen includes all or substantially all of the amino acids of the original naturally-occurring allergen, though in a different order.
摘要翻译:本文公开了由天然存在的变应原组装的低过敏性花叶病毒抗原。 还公开了制备这种低变应原性花叶病毒抗原的方法,特别是衍生自植物过敏原如Timothy草花粉(Phl p 1和Phl p 2)和桦树花粉(Bet v 1)的那些。 在特别优选的实施方案中,制备低变应原性镶嵌抗原的方法包括以下步骤:(a)将天然存在的变应原切割成至少两个,优选至少三个非重叠的肽片段,和(b)将肽片段 马赛克抗原包括原始天然存在的变应原的所有或基本上全部的氨基酸,尽管以不同的顺序。
摘要:
The present invention relates to a pharmaceutical composition containing a peptide and a pharmaceutically acceptable carrier or diluent wherein the peptide has a length of 8 to 50 amino acids, at least three preferably consecutive amino acids of the peptide are identical to at least three amino acids which appear in close vicinity on the molecular surface of an allergenic protein, and said at least three amino acids are solvent-exposed amino acids in the allergenic protein. The invention also concerns a method for the preparation of the pharmaceutical composition.
摘要:
The invention relates to a hypoallergenic immunogenic molecule derived from the Phl p 6 allergen, wherein the Phl p 6 molecule has an N-terminal and/or C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity. The invention also relates to a hypoallergenic immunogenic combination of molecules derived from the Phl p 6 allergen, comprising (i) a Phl p 6 molecule having an N-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, and (ii) a Phl p 6 molecule having a C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, which two molecules together encompass the complete sequence of Phl p 6. The invention further relates to the use of the hypoallergenic immunogenic molecule or molecule mixture in hyposensitization and diagnosis.
摘要:
The present invention is drawn to an immunogen derived from a protein allergen, which is a) a non-anaphylactic immunogenic recombinant fragment of the protein allergen which contains an IgG epitope partly but not wholly overlapping an IgE epitope of the protein allergen; b) a polymeric form of the fragment, in which the fragment constitutes the monomeric units; or c) a non-anaphylactic recombinant polymeric form of the protein allergen having 2–10 monomeric units, in which the protein allergen constitutes the monomeric units. The present invention is further drawn to the use of the immunogen for in vitro diagnoses of type I allergy and hyposensitization.
摘要:
The present invention relates to a novel drug candidate having a potential for universal therapy of allergy and asthma.The invention provides a Fab (antibody fragment), having the following characteristics: a) inhibits the IgE-FcεRI interaction; b) binds to free and cell-bound IgE; and c) is non-anaphylactic.